Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Treatment of low-risk endometrial cancer

Steven C Plaxe, MD
Arno J Mundt, MD
Section Editor
Barbara Goff, MD
Deputy Editors
Sadhna R Vora, MD
Sandy J Falk, MD, FACOG


Endometrial cancer is cancer of the uterine lining. Surgery is the standard treatment for women with low-risk endometrial cancer, and the prognosis is usually excellent. Adjuvant therapy is most often not recommended with low-risk disease.

This review will focus on the options for adjuvant treatment in endometrial cancer and will explain why it is not recommended for women with low-risk disease. The treatment of intermediate- and high-risk endometrial cancers is discussed separately.

(See "Approach to adjuvant treatment of endometrial cancer".)

(See "Adjuvant treatment of intermediate-risk endometrial cancer".)

(See "Adjuvant treatment of high-risk endometrial cancers".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 15, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Madom LM, Brown AK, Lui F, et al. Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma. Gynecol Oncol 2007; 107:75.
  2. Kizer NT, Gao F, Guntupalli S, et al. Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma. Ann Surg Oncol 2011; 18:1419.
  3. Brown AK, Madom L, Moore R, et al. The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes. Gynecol Oncol 2007; 105:55.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelnes): Uterine neoplasms. Version 2.2012. http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (Accessed on December 09, 2011).
  5. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55.
  6. Eifel PJ, Ross J, Hendrickson M, et al. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983; 52:1026.
  7. Orr JW Jr, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 1997; 176:777.
  8. Straughn JM Jr, Huh WK, Kelly FJ, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002; 84:194.
  9. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.
  10. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012; :CD003916.
  11. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol 2013; 31:3951.
  12. Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19:873.
  13. Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011; :CD001040.
  14. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101:520.
  15. Folsom AR, Anderson KE, Sweeney C, Jacobs DR Jr. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 2004; 94:740.
  16. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 2012; 126:176.
  17. Bjørge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010; 171:892.
  18. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011; 22:884.